The UK sector barely existed before November 2018 and now contains a wide range of providers of markedly different quality. For a patient trying to choose, the marketing is close to useless, since everyone claims specialist doctors, personalized care and rapid access.
The differences that matter are checkable, and most of them are checkable before you book anything.
Regulation is the starting point
The most basic filter is whether the provider is regulated at all, and by whom.
The Care Quality Commission regulates independent healthcare in England, and its interim policy position on cannabis-based medicinal products sets out what it requires. Specialist doctors working in independent healthcare must register with CQC for the regulated activity of treatment of disease, disorder and injury, and providers intending to prescribe these medicines must be able to demonstrate assurance around that prescribing.
CQC also makes a point that patients rarely hear from providers: most cannabis-based medicinal products are unlicensed, and treating patients with unlicensed medicines carries a higher risk than treating them with licensed ones, because they may not have been assessed for safety, quality and efficacy.
A clinic that explains this openly is behaving better than one that does not mention it.
Who is actually prescribing
Only doctors on the General Medical Council’s Specialist Register can prescribe unlicensed cannabis-based medicines, and they must work within the limits of their own competence.
That second clause does more work than people realize. A specialist in one field prescribing for a condition outside it is operating outside GMC expectations regardless of their register status. A clinic treating a broad range of conditions should be able to tell you which specialist handles which, and the fact that names and specialties are publicly verifiable makes this an easy check.
Non-medical prescribers cannot prescribe these products at all. If you are offered a prescription by someone who is not a doctor on the Specialist Register, that is disqualifying rather than a minor irregularity. Directories comparing the best medical cannabis clinics are a reasonable way to assemble a shortlist. Verifying the individual prescriber is what turns that shortlist into a decision.
The multidisciplinary question
Better clinics review cases through a multidisciplinary team rather than through a single clinician working alone.
The reason is not bureaucratic. Decisions about unlicensed medicines for complex conditions benefit from more than one perspective, particularly where a patient has multiple conditions or is taking other medicines with interaction potential.
Ask whether cases go to an MDT and how often. A provider that reviews only at initiation, or only when something goes wrong, is running a lighter process than one that reviews periodically.
What a good consultation looks like
The consultation itself is the most revealing signal, and it is available to you before any money changes hands in most cases.
A quality assessment covers full medical history rather than the presenting complaint alone, asks what has already been tried and why it did not work, discusses interactions with your current medicines, and covers side effects and the practical consequences of treatment including driving and employment.
It should also include a realistic conversation about what the evidence does and does not support for your condition. A clinician who presents this as reliably effective for everything is not describing the evidence base accurately.
If a consultation lasts ten minutes and ends with a prescription, that is information about the provider.
Continuity and follow-up
The sector’s most common failure is not the initial assessment. It is what happens afterwards.
Good practice involves scheduled follow-up, dose review, monitoring for adverse effects, and a named point of contact. Poor practice involves a prescription, a repeat mechanism, and no meaningful clinical contact until something goes wrong.
Ask directly: how often will I be reviewed, by whom, and what happens if I have a problem between appointments. Vague answers are answers.
Access is not uniform across the UK
One area that catches patients out is that the picture differs between the four nations, and providers do not always explain this clearly.
Regulation of independent healthcare, NHS structures and referral routes all vary, and a provider registered in England is regulated by a different body from one operating in Scotland, Wales or Northern Ireland. Guidance covering medical cannabis in Northern Ireland sets out how access works there specifically, and anyone outside England should check the position for their own nation rather than assuming English arrangements apply.
Pricing transparency
Cost structures in this sector are more variable than in most areas of private healthcare, and opacity is a warning sign.
A provider should be able to tell you, before you commit, what the initial consultation costs, what follow-ups cost, what the medicine itself costs per month, and whether prescription and dispensing fees are additional. Patients frequently discover the total is substantially more than the headline consultation fee suggested.
Be wary of anything structured to make comparison difficult, and of subscription models that bundle costs in ways you cannot itemize.
Questions worth asking before you book
Five, and they take one phone call.
Which regulator are you registered with, and what is your registration number? Which specialist would see me, and what is their specialty? Do cases go through a multidisciplinary team? What does the full first year cost, including medicine? And what does follow-up look like in practice?
A provider that answers all five without hesitation is demonstrating something more useful than any testimonial. One that deflects on any of them has told you what you needed to know.
This article is general information rather than medical advice. Whether treatment of any kind is appropriate for you is a question for a qualified clinician who has assessed you properly.
